Co-ultra PEALut Enhances Neuronal Recovery Following Moderate Traumatic Brain Injury (GLIA13)
Traumatic Brain Injury
About this trial
This is an interventional treatment trial for Traumatic Brain Injury focused on measuring Moderate brain trauma, Glialia, Neuroinflammation, Neuroprotection
Eligibility Criteria
Inclusion Criteria:
- Traumatic brain injuries
- Moderate trauma
- Glasgow Coma Score 9-13
- Loss of consciousness lasting >1 min
- post-traumatic amnesia >20 minutes
- CT scan Marshall Scale class II-VI.
Exclusion Criteria:
- Spinal cord injuries
- Pre-existing neurological disorders affecting the brain and/or the spinal cord
- Severe hypertension
- Diabetes, and chronic renal disease
- Remarkable chronic cerebravasculopathy of the CT
- Severe cognitive deficit.
Sites / Locations
- Department of Neurosurgery, University of MessinaRecruiting
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
Control Group
Study Group
All patients are treated by standard treatments according to patterns of severity and in the light of different variables, mainly represented by the conditions of cerebral hemodynamics. These procedures can be summarized as follows: Surgical evacuation of hemorrhagic masses and brain contusion Medical management aimed to maintenance of euvolemia and adequate brain perfusion. Prevention of secondary complications of critical illness included: preventive treatment of venous thromboembolism (VTE) and seizures Patient who undergo surgical treatment, will recieve also postoperative intensive care treatments including: position of the head high, lower values of end-tidal CO2, sedation with reduced metabolic consumption of O2, increase in plasma osmolarity by administration of mannitol in controlled doses or hypernatremia, therapeutic CSF drainage
Standard treatment plus specific treatment. The investigational agent, the co-ultraPEALut, is administered orally twice daily (every 12 h) for 180 days in association with the specific therapy (e.g., antiplatelet agents, anticoagulants, antiepileptic drugs) commonly administered to these patients and/or with drugs prescribed for comorbidities (i.e. diabetes, arterial hypertension).